The Prognostic Value of TTF-1/NKX2-1 in Lung Squamous Cell Carcinoma
暂无分享,去创建一个
Jun Wang | Kezhong Chen | Fan Yang | Xiao Li | Y. Liao
[1] F. Klauschen,et al. Pemetrexed-Based Chemotherapy Is Inferior to Pemetrexed-Free Regimens in Thyroid Transcription Factor 1 (TTF-1)-Negative, EGFR/ALK-Negative Lung Adenocarcinoma: A Propensity Score Matched Pairs Analysis. , 2020, Clinical lung cancer.
[2] D. Mu,et al. Mechanistic Study of TTF-1 Modulation of Cellular Sensitivity to Cisplatin , 2019, Scientific Reports.
[3] D. Civitareale,et al. TTF-1/Nkx2.1 functional connection with mutated EGFR relies on LRIG1 and β-catenin pathways in lung cancer cells. , 2018, Biochemical and biophysical research communications.
[4] B. Han,et al. Prognostic Impact of TTF-1 Expression in Non-Squamous Non-Small-Cell Lung Cancer: A Meta-Analysis , 2018, Journal of Cancer.
[5] Kwok-Kin Wong,et al. Non-small-cell lung cancers: a heterogeneous set of diseases , 2014, Nature Reviews Cancer.
[6] En-guo Chen,et al. Nkx2-1: a novel tumor biomarker of lung cancer , 2012, Journal of Zhejiang University SCIENCE B.
[7] Humam Kadara,et al. Abnormalities of the TITF-1 Lineage-Specific Oncogene in NSCLC: Implications in Lung Cancer Pathogenesis and Prognosis , 2011, Clinical Cancer Research.
[8] G. Kristiansen,et al. Periostin is up-regulated in high grade and high stage prostate cancer , 2010, BMC Cancer.
[9] R. Tavares,et al. Comparison of Thyroid Transcription Factor-1 Expression by 2 Monoclonal Antibodies in Pulmonary and Nonpulmonary Primary Tumors , 2010, Applied immunohistochemistry & molecular morphology : AIMM.
[10] T. Mok,et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. , 2009, The New England journal of medicine.
[11] I Petersen,et al. Genomic profiling identifies TITF1 as a lineage-specific oncogene amplified in lung cancer , 2008, Oncogene.
[12] Ping Wang,et al. Thyroid transcription factor in differentiating type II cells: regulation, isoforms, and target genes. , 2007, American journal of respiratory cell and molecular biology.
[13] J. Lafitte,et al. Thyroid transcription factor 1--a new prognostic factor in lung cancer: a meta-analysis. , 2006, Annals of oncology : official journal of the European Society for Medical Oncology.
[14] A Coldman,et al. Evaluation of immunohistochemical markers in non‐small cell lung cancer by unsupervised hierarchical clustering analysis: a tissue microarray study of 284 cases and 18 markers , 2004, The Journal of pathology.
[15] Dietel,et al. Thyroid transcription factor‐1 is the superior immunohistochemical marker for pulmonary adenocarcinomas and large cell carcinomas compared to surfactant proteins A and B , 2000, Histopathology.
[16] J. Whitsett,et al. Utility of surfactant protein B precursor and thyroid transcription factor 1 in differentiating adenocarcinoma of the lung from malignant mesothelioma. , 1999, Human pathology.
[17] J. Whitsett,et al. Thyroid Transcription Factor-1 and Cytokeratins 7 and 20 in Pulmonary and Breast Carcinoma , 1998, Acta Cytologica.
[18] F. Puglisi,et al. TTF-1 protein expression in pleural malignant mesotheliomas and adenocarcinomas of the lung. , 1998, Cancer letters.
[19] A. Kubo,et al. Expression of thyroid transcription factor-1 in 16 human lung cancer cell lines. , 2003, Lung cancer.
[20] C H Fox,et al. The T/ebp null mouse: thyroid-specific enhancer-binding protein is essential for the organogenesis of the thyroid, lung, ventral forebrain, and pituitary. , 1996, Genes & development.